Business and Finance
Germany's Merck KGaA agrees to buy UK biotech Silence Therapeutics for about $1.3 billion
The all-cash deal of US$20 per share adds an experimental treatment for the rare blood cancer polycythemia vera to Merck's pipeline. It is expected to close in early 2027.
